Pharmaceutical

Image

Europe Pterygium Drug Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Published Report
  • Jun 2022
  • Europe
  • 350 Pages
  • No of Tables: 230
  • No of Figures: 53

Europe Pterygium Drug Market, By Disease Type (Progressive Pterygium and Atrophic Pterygium), Stages (Stage 2, Stage 3, Stage 1, Stage 4), Treatment (Artificial Tears/Topical Lubricants and Steroid Eye Drops), Formulation (Eye Drops, Eye Ointments, Others), Mode of Purchase (Prescription and Over the Counter (OTC)), Population Type (Geriatric and Adults), End User (Hospitals, Specialty Clinics, Home Healthcare, Others), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, Others) - Industry Trends and Forecast to 2029.

Europe Pterygium Drug Market

Market Analysis and Insights

Pterygium is a common ocular surface lesion that begins in the limbal conjunctiva within the palpebral fissure and progresses to the cornea. It is named after the Greek word pterygos, which means "wing".  The lesion occurs more frequently at the nasal limbus than the temporal with a characteristic wing-like appearance.  UV exposure is strongly linked to the occurrence of pterygia. Individuals having a history of elevated UV exposure and those living closer to the equator have a higher incidence (outdoor work). According to certain research, males have a somewhat higher incidence than females, which could be due to a higher rate of UV exposure.

It can cause redness, inflammation, and a change in the look of the eye; it can create astigmatism, which can cause blurry vision; and it can cause a whitish or pinkish growth covering the front of the eye. It could affect one or both eyes.

Pterygium is diagnosed using a microscope to examine the front components of the eye during a full eye examination and based on the appearance of tissue growth on the cornea from the white area of the eye.

Data Bridge Market Research analyses that the global Europe pterygium drug market will grow at a CAGR of 4.8% during the forecast period of 2022 to 2029.

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customisable to 2019-2014)

Quantitative Units

Revenue in USD Million, Pricing in USD

Segments Covered

Disease Type (Progressive Pterygium and Atrophic Pterygium), Stages (Stage 2, Stage 3, Stage 1, Stage 4), Treatment (Artificial Tears/Topical Lubricants and Steroid Eye Drops.), Formulation (Eye Drops, Eye Ointments, Others), Mode of Purchase (Prescription and Over the Counter (OTC)), Population Type (Geriatric and Adults), End-User (Hospitals, Specialty Clinics, Home Healthcare, Others), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, Others)

Countries Covered

Russia, Spain, Turkey, Germany, Italy, United Kingdom, France, Hungary, Austria, Switzerland, Netherlands, Poland, Ireland, Norway, Lithuania, Rest of Europe

Market Players Covered

Johnson & Johnson Services, Inc. (U.S.), Novartis AG (Switzerland), Akorn Operating Company LLC (U.S.), Bausch & Lomb Incorporated (Canada), AbbVie Inc. (U.S.),  Prestige Consumer Healthcare Inc. (U.S.), Théa Laboratories (France),  Wellona Pharma (India),  SAGER PHARMA (Hungary),  Sylentis (Spain), Bayer AG (Germany), Zydus Group, Amneal Pharmaceuticals LLC (India),  OASIS Medical (U.S.), Similasan Corporation (Switzerland), Alcon (Switzerland), and Santen Pharmaceutical Co., Ltd. (Japan)

Market Definition

Pterygium is a common ocular surface lesion that begins in the limbal conjunctiva within the palpebral fissure and progresses to the cornea. It is named after the Greek word pterygos, which means "wing".  The lesion occurs more frequently at the nasal limbus than the temporal with a characteristic wing-like appearance.  UV exposure is strongly linked to the occurrence of pterygia. Individuals having a history of elevated UV exposure and those living closer to the equator have a higher incidence (outdoor work). According to certain research, males have a somewhat higher incidence than females, which could simply be due to a higher rate of UV exposure.

Pterygium is diagnosed using a microscope to examine the front components of the eye during a full eye examination and based on the appearance of tissue growth on the cornea from the white area of the eye.

Europe Pterygium Drug Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:

Drivers

  • The rise in incidences and prevalences of ophthalmic disorders

According to data published in the National Library of Medicine (National Center for Biotechnology Information) in 2021, the prevalence rates vary in different places. It is most abundant in Cameron's "pterygium belt," which runs between 37° north and south of the equator.

The most common causes of pterygium include long-term exposure to ultraviolet (UV) light from the sun (most common cause) and eye irritation caused by hot, dry weather, wind, and dust. The affirmative factors state that this is the major driver for the global pterygium drugs market.

  • The rise in the geriatric population

With the growing geriatric population across the globe, the prevalence of ophthalmic diseases with severe ocular pain is also growing. According to a data provided published in "Global Prevalence of Blindness and Distance and Near Vision Impairment in 2020: progress towards the Vision 2020 targets and what the future holds" by "The Association for Research in Vision and Ophthalmology" (ARVO) estimated 41.9 million people were blind.

With the growing population, the pressure on the healthcare system is increasing. The demand for care and services is rising to treat the problem of Ophthalmol disorder, including pterygium. Therefore, the increasing geriatric population is a great opportunity for the Europe pterygium drug market.

Opportunities

  • Programs and initiatives to reduce the burden of eye diseases

The International agency to prevent blindness has launched several programs and initiatives with well-reputed NGOs and corporates to spread awareness and reduce the burden of eye diseases.

For instance,

  • International Agency endorses our Children's Vision and an initiative co-founded by the Brien Holden Vision Institute and the Vision For Life fund (created by Essilor) for the Prevention of Blindness (IAPB)

Restraints/Challenges

The growing prevalence of various ophthalmic disorders has also increased the necessity for timely treatments. However, the treatments and proper medication for ophthalmology disorders are not very cheap. Recent studies show that the price of topical steroids price is increasing in the past few years. Even though some topical ophthalmic steroids like prednisolone are mildly cheap, other advanced medications and eye drops are still expensive.

The Europe pterygium drug market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the pterygium drug market, contact Data Bridge Market Research for an Analyst Brief. Our team will help you make an informed market decision to achieve market growth.

Patient Epidemiology Analysis

The prevalence of ophthalmic disorders keeps showing a surge in growth due to the rise in chemical industries and pollution worldwide. Chemical burns and flash burns cause significant and severe ocular pain due to irritations over the eye surface.

According to data published in the National Library of Medicine (National Center for Biotechnology Information) in 2021, the prevalence rates vary in different places. It is most abundant in Cameron's "pterygium belt," which runs between 37° north and south of the equator. Pterygium prevalence has been reported to range from 0.3 to 29% worldwide.

The Europe pterygium drug market also provides detailed market analysis for patient analysis, prognosis, and cures. Prevalence, incidence, mortality, and adherence are some data variables available in the report. Direct or indirect impact analysis of epidemiology to the market growth are analyzed to create a more robust and cohot multivariate statistical model for forecasting the market in the growth period.

Post-COVID-19 Impact on Europe Pterygium Drug Market

COVID-19 has negatively affected the market. Lockdowns and isolations during pandemics complicate disease management and medication adherence. The lack of access to healthcare facilities for routine treatment and medication administration will further impact the market.

Recent Development

In April 2021, Alcon announced the launch of Systane hydration multi-dose preservative-free lubricating eye drops in the U.S. The product is a new option for patients suffering from aqueous deficient dry eye and acts as a protectant for further relief from irritation and dryness of the eye. This helped the company to increase its portfolio

Europe Pterygium Drug Market Scope

The Europe pterygium drug market is categorized into eight notable segments based on disease type, stages, treatment, formulation, mode of purchase, population type, end-user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Disease Type

  • Progressive Pterygium
  • Atrophic Pterygium

Based on disease, the Europe pterygium drug market is segmented into progressive pterygium and atrophic pterygium.

Stages

  • Stage 1
  • Stage 2
  • Stage 3
  • Stage 4

Based on stages, the Europe pterygium drug market is segmented into stage 1, stage 2, stage 3, and stage 4.

Treatment

  • Artificial Tears/Topical Lubricants
  • Steroid Eye Drops

Based on treatment, the Europe pterygium drug market is segmented into artificial tears/topical lubricants, and steroid eye drops.

Formulation

  • Eye Drops
  • Eye Ointments
  • Others

Based on formulation, the Europe pterygium drug market is segmented into eye drops, ointments, and others.

Mode of Purchase

  • Prescription
  • Over the Counter (OTC)

Based on mode of purchase, the Europe pterygium drug market is segmented into prescription and over-the-counter (OTC).

Population Type

  • Geriatric
  • Adults

Based on population type, the Europe pterygium drug market is segmented into geriatric and adults.

End-User

  • Hospitals
  • Specialty Clinics
  • Home Healthcare
  • Others

Based on end-user, the Europe pterygium drug market is segmented into hospitals, specialty clinics, home healthcare, and others.

Distribution Channel

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies
  • Others

Based on distribution channels, the Europe pterygium drug market is segmented into retail pharmacies, hospital pharmacies, and online pharmacies.

Europe Pterygium Drug Market Regional Analysis/Insights

Europe pterygium drug market is analyzed, and market size insights and trends are provided by country, disease type, stages, treatment, formulation, mode of purchase, population type, end-user, and distribution channel. as referenced above.

The countries covered in the Europe pterygium drug market report are Russia, Spain, Turkey, Germany, Italy, United Kingdom, France, Hungary, Austria, Switzerland, Netherlands, Poland, Ireland, Norway, Lithuania, Rest of Europe.

Europe pterygium drug market is expected to grow due to the increasing prevalence of ophthalmic disorders and rising awareness of treatment for eye diseases.

Russia is expected to dominate the Europe pterygium drug market in terms of market share and revenue and will continue to flourish its dominance during the forecast period. This is due to the high population suffering from pterygium.

The country section of the report also provides individual market impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of global brands and their challenges faced due to high competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Europe Pterygium Drug Market Share Analysis

Europe pterygium drug market competitive landscape provides details of the competitor. Details include company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, European presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the pterygium drug market.

Some of the major players operating in the global Europe pterygium drug market are Johnson & Johnson Services, Inc., Novartis AG, Akorn Operating Company LLC, Bausch & Lomb Incorporated, AbbVie Inc.,  Prestige Consumer Healthcare Inc.,  Théa Laboratories,  Wellona Pharma,  SAGER PHARMA,  Sylentis, Bayer AG, Zydus Group, Amneal Pharmaceuticals LLC,  OASIS Medical, Similasan Corporation, Alcon, and Santen Pharmaceutical Co., Ltd. among others.

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by the DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning grids, Market Time Line Analysis, Market Overview and Guide, Company Positioning grids, Company Market Share Analysis, Standards of Measurement, Europe Vs Regional, and Vendor Share Analysis. Please request an analyst call in case of further inquiry.


SKU-

TABLE 1 EUROPE PTERYGIUM DRUG MARKET, PIPELINE ANALYSIS

TABLE 2 EUROPE PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 3 EUROPE PROGRESSIVE PTERYGIUM IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 4 EUROPE ATROPHIC PTERYGIUM IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 5 EUROPE PTERYGIUM DRUG MARKET , BY STAGES, 2020-2029 (USD MILLION)

TABLE 6 EUROPE STAGE 2 IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 7 EUROPE STAGE 3 IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 8 EUROPE STAGE 1 IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 9 EUROPE STAGE 4 IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 10 EUROPE PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 11 EUROPE ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 12 EUROPE ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 13 EUROPE STEROID EYE DROPS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 14 EUROPE STEROID EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 15 EUROPE KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 16 EUROPE PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 17 EUROPE EYE DROPS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 18 EUROPE EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 19 EUROPE EYE OINTMENTS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 20 EUROPE OTHERS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 21 EUROPE PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)

TABLE 22 EUROPE PRESCRIPTION IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 23 EUROPE OVER THE COUNTER (OTC) IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 24 EUROPE PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 25 EUROPE GERIATRICS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 26 EUROPE ADULTS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 27 EUROPE PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 28 EUROPE HOSPITALS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 29 EUROPE SPECIALTY CLINICS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 30 EUROPE HOME HEALTHCARE IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 31 EUROPE OTHERS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 32 EUROPE PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 33 EUROPE RETAIL PHARMACIES IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 34 EUROPE HOSPITAL PHARMACIES IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 35 EUROPE ONLINE PHARMACIES IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 36 EUROPE OTHERS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 37 EUROPE PTERYGIUM DRUG MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 38 EUROPE PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 39 EUROPE PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)

TABLE 40 EUROPE PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 41 EUROPE ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 42 EUROPE STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 43 EUROPE KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 44 EUROPE PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 45 EUROPE EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 46 EUROPE PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)

TABLE 47 EUROPE PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 48 EUROPE PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 49 EUROPE PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 50 RUSSIA PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 51 RUSSIA PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)

TABLE 52 RUSSIA PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 53 RUSSIA ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 54 RUSSIA STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 55 RUSSIA KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 56 RUSSIA PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 57 RUSSIA EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 58 RUSSIA PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)

TABLE 59 RUSSIA PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 60 RUSSIA PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 61 RUSSIA PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 62 SPAIN PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 63 SPAIN PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)

TABLE 64 SPAIN PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 65 SPAIN ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 66 SPAIN STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 67 SPAIN KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 68 SPAIN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 69 SPAIN EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 70 SPAIN PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)

TABLE 71 SPAIN PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 72 SPAIN PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 73 SPAIN PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 74 TURKEY PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 75 TURKEY PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)

TABLE 76 TURKEY PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 77 TURKEY ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 78 TURKEY STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 79 TURKEY KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 80 TURKEY PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 81 TURKEY EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 82 TURKEY PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)

TABLE 83 TURKEY PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 84 TURKEY PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 85 TURKEY PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 86 GERMANY PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 87 GERMANY PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)

TABLE 88 GERMANY PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 89 GERMANY ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 90 GERMANY STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 91 GERMANY KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 92 GERMANY PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 93 GERMANY EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 94 GERMANY PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)

TABLE 95 GERMANY PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 96 GERMANY PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 97 GERMANY PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 98 ITALY PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 99 ITALY PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)

TABLE 100 ITALY PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 101 ITALY ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 102 ITALY STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 103 ITALY KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 104 ITALY PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 105 ITALY EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 106 ITALY PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)

TABLE 107 ITALY PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 108 ITALY PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 109 ITALY PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 110 U.K. PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 111 U.K. PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)

TABLE 112 U.K. PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 113 U.K. ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 114 U.K. STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 115 U.K. KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 116 U.K. PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 117 U.K. EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 118 U.K. PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)

TABLE 119 U.K. PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 120 U.K. PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 121 U.K. PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 122 FRANCE PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 123 FRANCE PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)

TABLE 124 FRANCE PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 125 FRANCE ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 126 FRANCE STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 127 FRANCE KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 128 FRANCE PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 129 FRANCE EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 130 FRANCE PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)

TABLE 131 FRANCE PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 132 FRANCE PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 133 FRANCE PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 134 HUNGARY PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 135 HUNGARY PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)

TABLE 136 HUNGARY PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 137 HUNGARY ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 138 HUNGARY STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 139 HUNGARY KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 140 HUNGARY PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 141 HUNGARY EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 142 HUNGARY PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)

TABLE 143 HUNGARY PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 144 HUNGARY PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 145 HUNGARY PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 146 AUSTRIA PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 147 AUSTRIA PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)

TABLE 148 AUSTRIA PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 149 AUSTRIA ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 150 AUSTRIA STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 151 AUSTRIA KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 152 AUSTRIA PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 153 AUSTRIA EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 154 AUSTRIA PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)

TABLE 155 AUSTRIA PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 156 AUSTRIA PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 157 AUSTRIA PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 158 SWITZERLAND PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 159 SWITZERLAND PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)

TABLE 160 SWITZERLAND PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 161 SWITZERLAND ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 162 SWITZERLAND STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 163 SWITZERLAND KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 164 SWITZERLAND PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 165 SWITZERLAND EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 166 SWITZERLAND PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)

TABLE 167 SWITZERLAND PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 168 SWITZERLAND PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 169 SWITZERLAND PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 170 NETHERLANDS PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 171 NETHERLANDS PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)

TABLE 172 NETHERLANDS PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 173 NETHERLANDS ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 174 NETHERLANDS STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 175 NETHERLANDS KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 176 NETHERLANDS PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 177 NETHERLANDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 178 NETHERLANDS PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)

TABLE 179 NETHERLANDS PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 180 NETHERLANDS PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 181 NETHERLANDS PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 182 POLAND PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 183 POLAND PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)

TABLE 184 POLAND PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 185 POLAND ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 186 POLAND STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 187 POLAND KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 188 POLAND PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 189 POLAND EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 190 POLAND PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)

TABLE 191 POLAND PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 192 POLAND PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 193 POLAND PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 194 IRELAND PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 195 IRELAND PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)

TABLE 196 IRELAND PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 197 IRELAND ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 198 IRELAND STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 199 IRELAND KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 200 IRELAND PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 201 IRELAND EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 202 IRELAND PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)

TABLE 203 IRELAND PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 204 IRELAND PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 205 IRELAND PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 206 NORWAY PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 207 NORWAY PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)

TABLE 208 NORWAY PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 209 NORWAY ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 210 NORWAY STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 211 NORWAY KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 212 NORWAY PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 213 NORWAY EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 214 NORWAY PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)

TABLE 215 NORWAY PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 216 NORWAY PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 217 NORWAY PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 218 LITHUANIA PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 219 LITHUANIA PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)

TABLE 220 LITHUANIA PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 221 LITHUANIA ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 222 LITHUANIA STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 223 LITHUANIA KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 224 LITHUANIA PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 225 LITHUANIA EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 226 LITHUANIA PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)

TABLE 227 LITHUANIA PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 228 LITHUANIA PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 229 LITHUANIA PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 230 REST OF EUROPE PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Free Sample Report

CHOOSE LICENCE TYPE

  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials